Florida Senate
-
2025
CS for CS for SB 1800
By
the Appropriations Committee on Health and Human Services;
the Committee on Health Policy; and Senator Calatayud
588-03164-25603-03438-25 20251800c120251800c2
1 A bill to be entitled
5 unchanged paragraphs
2 An act relating to Parkinson’s disease; creating s.
3 1004.4352, F.S.; providing a short title; providing
4 legislative findings; defining terms; establishing the
5 Consortium for Parkinson’s Disease Research within the
6 University of South Florida; establishing the
7 Parkinson’s Disease Research Board; providing for the
8 membership and duties of the board; requiring the board to direct
9 board to direct the operations of the consortium and to annually adopt;
10 aproviding planduties forof Parkinson’sthe diseaseconsortium researchdirector; providing
11 research requirements for the plan; requiring the
12 board to award funds to board members for certain
1113 dutiespurposes; ofrequiring the consortiumboard director;to providingissue researchan annual
12 requirements for the plan; requiring the board to
13 award funds to board members for certain purposes;
14 requiring the board to issue an annual report to the
1514 report to the Governor and Legislature by a specified date;
1615 date; providing appropriations; providing an effective date.
16 date.
17
50 unchanged paragraphs
18 Be It Enacted by the Legislature of the State of Florida:
19
20 Section 1. Section 1004.4352, Florida Statutes, is created
21 to read:
22
1004.4352
Parkinson’s disease research.—
23
(1)
SHORT TITLE.—This section may be cited as the
24
“Parkinson’s Disease Research Act.”
25
(2)
LEGISLATIVE FINDINGS.—The Legislature finds that:
26
(a)
Parkinson’s disease is a progressive neurological
27
disorder affecting approximately one million Americans, with an
28
estimated 90,000 new diagnoses each year.
29
(b)
Currently, there is no cure for Parkinson’s disease,
30
and innovative research is essential to advance therapies,
31
improve patient outcomes, and alleviate the burden of the
32
disease.
33
(3)
DEFINITIONS.—As used in this section, the term:
34
(a)
“Board” means the Parkinson’s Disease Research Board.
35
(b)
“Consortium” means the Consortium for Parkinson’s
36
Disease Research.
37
(4)
CONSORTIUM FOR PARKINSON’S DISEASE RESEARCH.—
38
(a)
There is established within the University of South
39
Florida the Consortium for Parkinson’s Disease Research which
40
shall consistbe composed of public and private universities. The purpose ofand
41
the consortium is to conduct rigorous scientific research and
academic medical centers. The purpose of the consortium is to
42
disseminate such research.
conduct rigorous scientific research and disseminate such
43
research.
44
(b)
The Parkinson’s Disease Research Board is established
4445
to direct the operations of the consortium. The board shall be
4546
composed of members representing each participating university
46
and appointed by the president of each participating university.
47
Board members must have experience in a variety of scientific
or academic medical center, appointed by the president or chief
48
fields, including, but not limited to, neurology, psychology,
executive officer, respectively, of each participating
49
nutrition, and genetics. Members shall be appointed to 4-year
university or academic medical center. Board members must,
50
terms and may be reappointed to serve additional terms. The
collectively, have experience in a variety of scientific fields,
51
chair shall be elected by the board from among its members to
including, but not limited to, neurology, psychology, nutrition,
52
serve a 2-year term. The board shall meet at least semiannually
and genetics. Members shall be appointed to 4-year terms and may
53
at the call of the chair or, in his or her absence or
be reappointed to serve additional terms. The chair shall be
54
incapacity, the vice chair. Four members constitute a quorum. A
elected by the board from among its members to serve a 2-year
55
majority vote of the members present is required for all actions
term. The board shall meet at least semiannually at the call of
56
of the board. The board may prescribe, amend, and repeal a
the chair or, in his or her absence or incapacity, the vice
57
charter governing the manner in which it conducts its business.
chair. Four members constitute a quorum. A majority vote of the
58
Board members shall serve without compensation, but are entitled
members present is required for all actions of the board. The
59
to receive reimbursement for travel expenses by the consortium
board may prescribe, amend, and repeal a charter governing the
60
or the organization he or she represents in accordance with s.
manner in which it conducts its business. Board members shall
61
112.061.
serve without compensation, but are entitled to receive
62
reimbursement for travel expenses by the consortium or the
63
organization he or she represents in accordance with s. 112.061.
64
(c)
The consortium shall be administered by a director, who
6365
shall be appointed by and serve at the pleasure of the board.
6466
The director shall, subject to the approval of the board:
6567
1.
Propose a budget for the consortium.
6668
2.
Foster the collaboration of scientists, researchers, and
6769
other appropriate personnel in accordance with the consortium’s
68
70
charter.
69
71
3.
Engage individuals in public and private university and
70
programs relevant to the consortium’s work to participate in the
71
consortium.
72
academic medical center
programs relevant to the consortium’s
73
work to participate in the consortium.
74
4.
Identify and prioritize the research to be conducted by
7375
the consortium.
7476
5.
Prepare a plan for Parkinson’s disease research for
7577
submission to the board.
7678
6.
Apply for grants to obtain funding for research
7779
conducted by the consortium.
7880
7.
Perform other duties as determined by the board.
79
81
(d)
The board shall annually adopt a plan for Parkinson’s
8082
disease research. The plan must organize a program of research
8183
that contributes to the body of scientific knowledge on the
8284
causes, mechanisms, and potential treatments for Parkinson’s
8385
disease and the prevalence of Parkinson’s disease in first
8486
responders. The board must award funds to members of the
8587
consortium to perform research consistent with the plan.
8688
(e)
By October 15 of each year, the board shall issue a
8789
report to the Governor, the President of the Senate, and the
88
90
Speaker of the House of Representatives on research projects,
8991
research findings, community outreach initiatives, and future
9092
plans for the consortium.
9193 Section 2.
(1)
Subject to appropriations from the General
9294
Appropriations Act, 67
percent
of funds
appropriated are
9395
directed to the University of South Florida for Parkinson’s
9496
disease research including, but not limited to, identifying the
9597
genetic origin of the disease and developing therapeutic
9698
interventions to slow or stop the progression of the disease.
9799
(2)
Subject to appropriations from the General
98
100
Appropriations Act, 33
percent
of funds appropriated
are
99
101
directed to the University of South Florida for the Consortium
100102
for Parkinson’s Disease Research.
101103 Section 3. This act shall take effect July 1, 2025.